Your AI-Trained Oncology Knowledge Connection!

Ben George, MD

Articles

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

January 3rd 2022

Closing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.

Evaluating the REFLECT Trial of Lenvatinib in Unresectable HCC

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

January 3rd 2022

Shifting their focus to the REFLECT trial of lenvatinib in unresectable hepatocellular carcinoma, panelists consider use of tyrosine kinase inhibition in this setting.

Unresectable HCC: Interpreting Data From the IMbrave150 Trial

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

January 3rd 2022

A panel of experts review data from the IMbrave150 trial of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma and consider implications for treatment.

Defining the Role of Adjuvant Therapy for HCC

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

January 3rd 2022

A brief discussion on the potential role for adjuvant therapy in patients with hepatocellular carcinoma.

Case 3: Selecting Therapy for Metastatic HCC

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

January 3rd 2022

Taking recent clinical trial data into account, panelists consider the best treatment option for a patient with metastatic hepatocellular carcinoma.

Case 3: Multidisciplinary Care in HCC Management

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

January 3rd 2022

In the context of metastatic hepatocellular carcinoma, panelists reflect on the value of multidisciplinary care at their institutions.

Case 3: A Patient With Metastatic HCC

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

January 3rd 2022

After introducing the third case, a patient with metastatic hepatocellular carcinoma, experts share their perspectives on the optimal diagnosis and work-up of advanced disease.

Case 2: A Patient With Solitary HCC <3 cm and a History of Cirrhosis

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

December 10th 2021

Moving on to the second case, the panel reviews optimal treatment strategies for a 74-year-old woman with solitary hepatocellular carcinoma <3 cm and a history of cirrhosis

Case 1: Real-World Experience With Y90 TARE in Unresectable HCC

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

December 10th 2021

Panelists discuss real-world experience with Y90 transarterial radioembolization for patients with unresectable hepatocellular carcinoma and highlight practical advice.

Case 1: The LEGACY Study of Y90 Radioembolization in Unresectable HCC

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

December 10th 2021

Shared insight on the results of the LEGACY study, which utilized Y90 transarterial radioembolization for patients with unresectable hepatocellular carcinoma.

Case 1: Combining Systemic and Locoregional Therapies in HCC

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

December 10th 2021

Centered on the patient case of solitary hepatocellular carcinoma, panelists consider the combination of locoregional and systemic therapies to improve outcomes.

Case 1: A Diagnosis of Solitary HCC ≥3 cm

Aparna Kalyan, MD;Ben George, MD;Edward S. Kim, MD, MBA, FACP, FASCO;Parvez Mantry, MD

November 24th 2021

Expert perspectives on the case of a 70-year-old man who presents and is diagnosed with solitary hepatocellular carcinoma measuring greater than 3cm.